Biologics Safety Testing market growth at a CAGR of ~ 13% from 2021 to 2027
The global Biologics Safety Testing market gathered revenue around USD 2.0 Billion in 2020 and market is set to grow USD 8.1 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 13% during the prediction period 2021 to 2027. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Biologics Safety Testing market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Biologics Safety Testing market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Biologics Safety Testing market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
North America accounted for the largest share of the Biologics safety testing market in 2020.
North America accounted for the largest share of the biologics safety testing market in 2020. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. Growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing awareness among consumers about product safety, and the presence of major market players in this region are also driving the market for biologics safety testing in North America.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Significant Market Participants Operational in the Biologics Safety Testing Market are: Maravai Lifesciences (US), Associates of Cape Cod, Inc. (US), bioMérieux SA (France), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Nelson Laboratories, LLC (US), Bio-Rad Laboratories, Inc. (US) and QIAGEN (Germany), Agilent Technologies, Inc. (US), Pacific BioLabs (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), FUJIFILM Wako Pure Chemical Corporation (Japan), and Almac Group (UK). Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), and Eurofins Scientific (Luxembourg).
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Biologics Safety Testing Market, by Product & Services
Biologics Safety Testing Market, by Application
Biologics Safety Testing Market, by Test Type
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biologics Safety Testing Market, By Product & Services
7.1. Biologics Safety Testing Market, by Product & Services, 2021-2027
7.1.1. Consumables
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Instrument
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Services
7.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Biologics Safety Testing Market, By Application
8.1. Biologics Safety Testing Market, by Application, 2021-2027
8.1.1. Vaccine Manufacturing
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Monoclonal Antibodies Manufacturing
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Cellular & Gene Therapy Products Manufacturing
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Blood and Blood Products Manufacturing
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Other Application
8.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Biologics Safety Testing Market, By End User
9.1. Biologics Safety Testing Market, by End User, 2021-2027
9.1.1. Endotoxin Test
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Sterility Test
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Mycoplasma Tests
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Bioburden Tests
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Residual Host-cell Proteins & DNA Detection Tests
9.1.5.1. Market Revenue and Forecast (2016-2027)
1.1.1. Virus safety Test
1.1.1.1. Market Revenue and Forecast (2016-2027)
Chapter 2. Global Biologics Safety Testing Market, Regional Estimates and Trend Forecast
2.1. North America
2.1.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.1.2. Market Revenue and Forecast, by Application (2016-2027)
2.1.3. Market Revenue and Forecast, by End User (2016-2027)
2.1.4. U.S.
2.1.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.1.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.1.5. Rest of North America
2.1.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.1.5.3. Market Revenue and Forecast, by End User (2016-2027)
2.2. Europe
2.2.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.2.2. Market Revenue and Forecast, by Application (2016-2027)
2.2.3. Market Revenue and Forecast, by End User (2016-2027)
2.2.4. UK
2.2.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.2.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.2.5. Germany
2.2.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.2.5.3. Market Revenue and Forecast, by End User (2016-2027)
2.2.6. France
2.2.6.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
2.2.6.3. Market Revenue and Forecast, by End User (2016-2027)
2.2.7. Rest of Europe
2.2.7.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
2.2.7.3. Market Revenue and Forecast, by End User (2016-2027)
2.3. APAC
2.3.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.3.2. Market Revenue and Forecast, by Application (2016-2027)
2.3.3. Market Revenue and Forecast, by End User (2016-2027)
2.3.4. India
2.3.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.3.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.3.5. China
2.3.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.3.5.3. Market Revenue and Forecast, by End User (2016-2027)
2.3.6. Japan
2.3.6.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
2.3.6.3. Market Revenue and Forecast, by End User (2016-2027)
2.3.7. Rest of APAC
2.3.7.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
2.3.7.3. Market Revenue and Forecast, by End User (2016-2027)
2.4. MEA
2.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.4.4. GCC
2.4.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.4.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.4.5. North Africa
2.4.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.4.5.3. Market Revenue and Forecast, by End User (2016-2027)
2.4.6. South Africa
2.4.6.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
2.4.6.3. Market Revenue and Forecast, by End User (2016-2027)
2.4.7. Rest of MEA
2.4.7.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
2.4.7.3. Market Revenue and Forecast, by End User (2016-2027)
2.5. Latin America
2.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.5.3. Market Revenue and Forecast, by End User (2016-2027)
2.5.4. Brazil
2.5.4.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
2.5.4.3. Market Revenue and Forecast, by End User (2016-2027)
2.5.5. Rest of LATAM
2.5.5.1. Market Revenue and Forecast, by Product & Services (2016-2027)
2.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
2.5.5.3. Market Revenue and Forecast, by End User (2016-2027)
Chapter 3. Company Profiles
3.1. Maravai Lifesciences
3.1.1. Company Overview
3.1.2. Product Offerings
3.1.3. Financial Performance
3.1.4. Recent Initiatives
3.2. Associates of Cape Cod, Inc.
3.2.1. Company Overview
3.2.2. Product Offerings
3.2.3. Financial Performance
3.2.4. Recent Initiatives
3.3. bioMérieux SA
3.3.1. Company Overview
3.3.2. Product Offerings
3.3.3. Financial Performance
3.3.4. Recent Initiatives
3.4. Sartorius AG
3.4.1. Company Overview
3.4.2. Product Offerings
3.4.3. Financial Performance
3.4.4. Recent Initiatives
3.5. F. Hoffmann-La Roche Ltd
3.5.1. Company Overview
3.5.2. Product Offerings
3.5.3. Financial Performance
3.5.4. Recent Initiatives
3.6. Nelson Laboratories, LLC
3.6.1. Company Overview
3.6.2. Product Offerings
3.6.3. Financial Performance
3.6.4. Recent Initiatives
3.7. Bio-Rad Laboratories, Inc.
3.7.1. Company Overview
3.7.2. Product Offerings
3.7.3. Financial Performance
3.7.4. Recent Initiatives
3.8. QIAGEN
3.8.1. Company Overview
3.8.2. Product Offerings
3.8.3. Financial Performance
3.8.4. Recent Initiatives
3.9. Agilent Technologies, Inc.
3.9.1. Company Overview
3.9.2. Product Offerings
3.9.3. Financial Performance
3.9.4. Recent Initiatives
3.10. Pacific BioLabs
3.10.1. Company Overview
3.10.2. Product Offerings
3.10.3. Financial Performance
3.10.4. Recent Initiatives
Chapter 4. Research Methodology
4.1. Primary Research
4.2. Secondary Research
4.3. Assumptions
Chapter 5. Appendix
5.1. About Us
5.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers